Vesicular stomatitis virus (VSV) therapy of tumors
- PMID: 11185959
- DOI: 10.1080/713803696
Vesicular stomatitis virus (VSV) therapy of tumors
Abstract
Vesicular stomatitis virus (VSV) is an essentially nonpathogenic negative-stranded RNA virus, the replication of which is extremely sensitive to the antiviral effects of interferon (IFN). We demonstrate here that VSV selectively induces the cytolysis of numerous transformed human cell lines in vitro, with all the morphological characteristics of apoptotic cell death. Importantly, VSV can also potently inhibit the growth of p53-null C6 glioblastoma tumors in vivo without infecting and replicating in normal tissue. With our previous findings demonstrating that primary cells containing the double-stranded RNA-activated protein kinase PKR and a functional IFN system are not permissive to VSV replication, these results suggest that signaling by IFN may be defective in many malignancies. Thus VSV might be useful in novel therapeutic strategies for targeting neoplastic disease.
Similar articles
-
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.Virology. 2004 Dec 5;330(1):34-49. doi: 10.1016/j.virol.2004.08.039. Virology. 2004. PMID: 15527832
-
VSV replication in neurons is inhibited by type I IFN at multiple stages of infection.Virology. 2005 Mar 15;333(2):215-25. doi: 10.1016/j.virol.2005.01.009. Virology. 2005. PMID: 15721356
-
Mechanism of interferon action. Interferon alpha inhibits vesicular stomatitis virus primary transcript accumulation in P1/eIF-2 alpha protein kinase-deficient human fibroblast cells.J Biol Regul Homeost Agents. 1987 Oct-Dec;1(4):157-65. J Biol Regul Homeost Agents. 1987. PMID: 2845723
-
Vesicular stomatitis virus as an oncolytic vector.Viral Immunol. 2004;17(4):516-27. doi: 10.1089/vim.2004.17.516. Viral Immunol. 2004. PMID: 15671748 Review.
-
VSV-tumor selective replication and protein translation.Oncogene. 2005 Nov 21;24(52):7710-9. doi: 10.1038/sj.onc.1209042. Oncogene. 2005. PMID: 16299531 Review.
Cited by
-
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Mol Ther. 2013. PMID: 23011032 Free PMC article.
-
Self-replicating vehicles based on negative strand RNA viruses.Cancer Gene Ther. 2023 Jun;30(6):771-784. doi: 10.1038/s41417-022-00436-7. Epub 2022 Feb 15. Cancer Gene Ther. 2023. PMID: 35169298 Free PMC article. Review.
-
Interferon response and viral evasion by members of the family rhabdoviridae.Viruses. 2009 Dec;1(3):832-51. doi: 10.3390/v1030832. Epub 2009 Nov 9. Viruses. 2009. PMID: 21994572 Free PMC article.
-
Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.J Virol. 2008 Jun;82(12):5735-49. doi: 10.1128/JVI.02601-07. Epub 2008 Apr 16. J Virol. 2008. PMID: 18417567 Free PMC article.
-
Advances in the mechanisms of action of cancer-targeting oncolytic viruses.Oncol Lett. 2018 Apr;15(4):4053-4060. doi: 10.3892/ol.2018.7829. Epub 2018 Jan 19. Oncol Lett. 2018. PMID: 29541169 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
